BackCaladrius Biosciences Overview

Caladrius Biosciences Receivables

Track Caladrius Biosciences's receivables ($0) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$0.00
↓ 100.00% YoYΔ $-750000.00 vs prior year quarter

Peer average

Loading

Caladrius Biosciences Receivables History

Loading

Caladrius Biosciences vs. peers: Receivables Comparison

Loading

Caladrius Biosciences Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Caladrius Biosciences (CLBS) FAQ

Caladrius Biosciences (CLBS) currently reports a receivables of $0 as of March 2026. That compares with $750K in the prior-year period — down 100.0% year over year. Use the charts on this page to explore Caladrius Biosciences's receivables history and peer comparisons.

Caladrius Biosciences's receivables decreased from $750K to $0 — a 100.0% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Caladrius Biosciences reported $0 in receivables as of March 2026. That compares with $750K in the prior-year period — down 100.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Caladrius Biosciences, and consider following CLBS for alerts when major investors trade the stock.

Caladrius Biosciences is classified in the Healthcare sector. On receivables, it currently shows $0. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CLBS with unrelated industries.